Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2008 June;52(2) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2008 June;52(2):174-84

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

FOREWORD  NON-STANDARD PET NUCLIDES


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2008 June;52(2):174-84

language: English

Towards new copper based radiopharmaceuticals

Barnard P. 1, Bayly S. 1, Betts H. 1, Bonnitcha P. 1, Christlieb M. 2, Dilworth J. 1, Holland J. 1, Pascu S. 1

1 Siemens Oxford Molecular Imaging Laboratory Chemistry Research Laboratory University of Oxford, Oxford, UK
2 Gray Cancer Institute Department of Radiation Oncology and Biology University of Oxford Mount Vernon Hospital, Northwood, UK


FULL TEXT  


This paper reviews the research in progress in Oxford on the chemical, spectroscopic and redox properties of bis(thiosemicarbazonato) complexes of zinc and copper in the context of the hypoxia selectivity of the copper(II) complex. Also, covered are synthetic strategies for modified complexes with a range of functional substituents and the in vitro and in vivo characteristics of two of these derivatives are described. Finally, the synthesis of some new bifunctional macrocyclic ligands is described and some of these give Cu(II) derivatives which cannot be reduced and are therefore resistant to reductive loss of copper in vivo.

top of page

Publication History

Cite this article as

Corresponding author e-mail